3 results
Primary objectiveTo evaluate if tralokinumab after 14 weeks of treatment (at steady state) changes the metabolism of substrates of CYP 1A2, 2C9, 2C19, 2D6, or 3A4 pathways in subjects with moderate-tosevere atopic dermatitisSecondary objectivesTo…
Primary objective of this study is to determine whether there are differences in occurrence of nausea, vomiting, use of escape medication, and in quality of life between smartphone-owners who downloaded the App, and smartphone-owners who did not use…
ObjectivesPrimary* To determine the efficacy (as assessed by radiographic progression free survival [rPFS]) of AZD4635 plus durvalumab and separately of AZD4635 plus durvalumab plus cabazitaxel in participants with mCRPC.Secondary* To evaluate the…